AbbVie (ABBV)
AbbVie on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on NYSE, classified by the SEC as pharmaceutical preparations.
15.6M
Short interest
settlement 2026-10-15
2.7
Days to cover
-1.4 days vs prior
14.2%
Short share of volume
2026-11-02
355
Fails to deliver
settlement 2026-10-13
Wed 3 Feb
Next earnings
estimated date
-$8.2M
Insider flow, 90 days
0 buys, 1 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in ABBV is 15,582,821 shares, down 3,911,735 shares over the last month. Over the last 48 readings it ranged from 14,700,538 shares (13 June 2025) to 25,110,220 shares (13 March 2026). The latest reading sits at the bottom of that range. At the reported average volume of 5.7M shares a day that is 2.7 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/abbv" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 15,582,821 | -4.3% | 5,721,041 | 2.72 |
| 2026-09-30 | 16,280,646 | -16.5% | 3,936,493 | 4.14 |
| 2026-09-15 | 19,494,556 | -0.1% | 4,347,900 | 4.48 |
| 2026-08-31 | 19,514,024 | +6.6% | 4,431,865 | 4.40 |
| 2026-08-14 | 18,299,894 | -18.8% | 5,120,103 | 3.57 |
| 2026-07-31 | 22,547,839 | -0.4% | 5,670,476 | 3.98 |
| 2026-07-15 | 22,632,412 | +3.4% | 6,559,915 | 3.45 |
| 2026-06-30 | 21,899,078 | -6.6% | 12,548,298 | 1.75 |
| 2026-06-15 | 23,446,826 | +1.2% | 5,150,656 | 4.55 |
| 2026-05-29 | 23,158,744 | +2.5% | 5,422,513 | 4.27 |
| 2026-05-15 | 22,590,034 | +8.1% | 5,670,258 | 3.98 |
| 2026-04-30 | 20,907,964 | -4.3% | 7,711,618 | 2.71 |
| 2026-04-15 | 21,845,453 | +8.6% | 5,885,786 | 3.71 |
| 2026-03-31 | 20,125,180 | -19.9% | 8,202,339 | 2.45 |
| 2026-03-13 | 25,110,220 | +15.5% | 6,795,131 | 3.70 |
| 2026-02-27 | 21,748,668 | -4.9% | 6,019,787 | 3.61 |
| 2026-02-13 | 22,876,092 | +16.2% | 8,360,159 | 2.74 |
| 2026-01-30 | 19,684,551 | -10.7% | 7,106,876 | 2.77 |
| 2026-01-15 | 22,042,536 | +11.9% | 7,499,512 | 2.94 |
| 2025-12-31 | 19,705,568 | +9.0% | 5,136,946 | 3.84 |
| 2025-12-15 | 18,075,534 | -0.7% | 5,046,976 | 3.58 |
| 2025-11-28 | 18,209,156 | -2.8% | 6,345,817 | 2.87 |
| 2025-11-14 | 18,724,102 | -0.9% | 6,259,695 | 2.99 |
| 2025-10-31 | 18,891,139 | +4.5% | 5,096,113 | 3.71 |
| 2025-10-15 | 18,080,904 | +11.0% | 6,937,881 | 2.61 |
| 2025-09-30 | 16,289,679 | -1.6% | 6,278,492 | 2.59 |
| 2025-09-15 | 16,559,691 | +7.5% | 4,667,989 | 3.55 |
| 2025-08-29 | 15,397,504 | -9.4% | 4,542,870 | 3.39 |
| 2025-08-15 | 16,997,471 | +12.4% | 4,639,882 | 3.66 |
| 2025-07-31 | 15,126,296 | -3.1% | 5,268,153 | 2.87 |
| 2025-07-15 | 15,608,381 | -2.1% | 5,989,573 | 2.61 |
| 2025-06-30 | 15,951,832 | +8.5% | 7,985,434 | 2.00 |
| 2025-06-13 | 14,700,538 | -7.5% | 4,558,435 | 3.22 |
| 2025-05-30 | 15,889,428 | -20.3% | 5,778,163 | 2.75 |
| 2025-05-15 | 19,929,844 | +0.7% | 8,523,720 | 2.34 |
| 2025-04-30 | 19,795,764 | +17.5% | 8,388,568 | 2.36 |
| 2025-04-15 | 16,843,458 | -1.7% | 10,959,166 | 1.54 |
| 2025-03-31 | 17,142,376 | -13.0% | 7,715,000 | 2.22 |
| 2025-03-14 | 19,695,617 | +6.4% | 6,343,506 | 3.10 |
| 2025-02-28 | 18,506,353 | -5.7% | 6,618,147 | 2.80 |
| 2025-02-14 | 19,623,497 | +3.7% | 5,232,382 | 3.75 |
| 2025-01-31 | 18,931,401 | +4.3% | 6,934,408 | 2.73 |
| 2025-01-15 | 18,160,016 | +6.8% | 5,344,987 | 3.40 |
| 2024-12-31 | 17,003,576 | -8.3% | 6,202,845 | 2.74 |
| 2024-12-13 | 18,531,930 | -4.1% | 5,290,162 | 3.50 |
| 2024-11-29 | 19,324,304 | -4.2% | 7,366,002 | 2.62 |
| 2024-11-15 | 20,169,830 | +11.3% | 8,086,873 | 2.49 |
| 2024-10-31 | 18,125,235 | +12.0% | 5,839,781 | 3.10 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of ABBV volume is 14.2%, down 15.4 points over the last five sessions. Over the last 30 readings it ranged from 14.2% (2 November 2026) to 63.9% (2 October 2026). The latest reading sits at the bottom of that range. The latest reading is 25.4 points below the 30-session average of 39.6%, on 3.1M shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 446K | 3.1M | 14.2% | 1,743 |
| 2026-10-30 | 870K | 2.3M | 38.4% | 64 |
| 2026-10-29 | 510K | 1.6M | 31.6% | 3,646 |
| 2026-10-28 | 399K | 1.1M | 35.6% | 1,624 |
| 2026-10-27 | 368K | 1.1M | 34.2% | 3,629 |
| 2026-10-26 | 390K | 1.3M | 29.6% | 2,497 |
| 2026-10-23 | 367K | 1.6M | 22.6% | 1,042 |
| 2026-10-22 | 536K | 2.3M | 23.0% | 687 |
| 2026-10-21 | 453K | 1.7M | 26.8% | 5,796 |
| 2026-10-20 | 624K | 2.3M | 27.5% | 3,190 |
| 2026-10-19 | 585K | 1.4M | 40.8% | 514 |
| 2026-10-16 | 365K | 2.0M | 17.8% | 8,592 |
| 2026-10-15 | 1.1M | 2.8M | 39.5% | 16,656 |
| 2026-10-14 | 1.2M | 2.1M | 58.1% | 750 |
| 2026-10-13 | 875K | 2.1M | 41.4% | 5,430 |
| 2026-10-12 | 775K | 1.5M | 52.4% | 1,002 |
| 2026-10-09 | 658K | 1.4M | 46.9% | 1,419 |
| 2026-10-08 | 760K | 1.5M | 51.8% | 24 |
| 2026-10-07 | 982K | 2.0M | 48.8% | 1,856 |
| 2026-10-06 | 787K | 1.4M | 57.0% | 5,115 |
| 2026-10-05 | 1.2M | 2.3M | 51.1% | 850 |
| 2026-10-02 | 1.1M | 1.7M | 63.9% | 59 |
| 2026-10-01 | 649K | 1.5M | 43.9% | 1,616 |
| 2026-09-30 | 491K | 1.1M | 45.9% | 1,674 |
| 2026-09-29 | 586K | 1.3M | 45.6% | 3,078 |
| 2026-09-28 | 520K | 1.4M | 37.0% | 18,281 |
| 2026-09-25 | 265K | 708K | 37.5% | 1,828 |
| 2026-09-24 | 456K | 1.2M | 38.0% | 110 |
| 2026-09-23 | 549K | 1.2M | 47.6% | 722 |
| 2026-09-22 | 380K | 962K | 39.5% | 597 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 13 October 2026, the fails-to-deliver balance in ABBV is 355 shares, up 327 shares over the last settlement date. Over the last 30 readings it ranged from 3 shares (6 August 2026) to 99,862 shares (25 September 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-13 | 355 | $281.12 | $100K |
| 2026-10-09 | 28 | $272.42 | $8K |
| 2026-10-07 | 5,644 | $266.69 | $1.5M |
| 2026-10-05 | 16 | $262.82 | $4K |
| 2026-10-01 | 58 | $261.59 | $15K |
| 2026-09-29 | 4,780 | $266.28 | $1.3M |
| 2026-09-25 | 99,862 | $265.12 | $26.5M |
| 2026-09-24 | 37,439 | $265.08 | $9.9M |
| 2026-09-22 | 2,137 | $264.48 | $565K |
| 2026-09-18 | 590 | $264.02 | $156K |
| 2026-09-17 | 93 | $262.51 | $24K |
| 2026-09-16 | 19 | $263.04 | $5K |
| 2026-09-10 | 16,029 | $250.91 | $4.0M |
| 2026-09-08 | 15 | $256.46 | $4K |
| 2026-08-28 | 699 | $258.15 | $180K |
| 2026-08-26 | 6,988 | $265.79 | $1.9M |
| 2026-08-24 | 3,809 | $264.96 | $1.0M |
| 2026-08-13 | 13,102 | $248.76 | $3.3M |
| 2026-08-06 | 3 | $246.20 | $739 |
| 2026-08-04 | 27 | $245.10 | $7K |
| 2026-07-28 | 9 | $256.91 | $2K |
| 2026-07-27 | 9 | $259.36 | $2K |
| 2026-07-15 | 26,659 | $244.78 | $6.5M |
| 2026-07-13 | 2,297 | $248.08 | $570K |
| 2026-07-10 | 529 | $249.91 | $132K |
| 2026-07-07 | 18,801 | $254.76 | $4.8M |
| 2026-07-06 | 29,055 | $261.07 | $7.6M |
| 2026-07-02 | 18,819 | $251.06 | $4.7M |
| 2026-06-30 | 5,541 | $254.31 | $1.4M |
| 2026-06-29 | 6,047 | $253.35 | $1.5M |
Insider trades
SEC Form 4, newest first. JSONInsiders at ABBV reported 1 open-market sell worth $8.2M in the last 90 days and no open-market buys. Latest filing: Donoghoe Nicholas (EVP, CHIEF BUS/STRAT OFFICER) on 2026-08-14.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-08-14 | Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | Sell | 33K | $250.00 | $8.2M | 74K |
| 2026-08-14 | Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | Exercise or conversion | 33K | $79.02 | $2.6M | 107K |
| 2026-05-08 | Quaggin Susan E | Director | Grant | 1K | $0.00 | $0 | 4K |
| 2026-05-08 | Davis Jennifer L. | Director | Grant | 1K | $0.00 | $0 | 4K |
| 2026-05-08 | MEYER MELODY B | Director | Grant | 1K | $0.00 | $0 | 18K |
| 2026-05-08 | BURNSIDE WILLIAM H.L. | Director | Grant | 1K | $0.00 | $0 | 28K |
| 2026-05-08 | Hart Brett J | Director | Grant | 1K | $0.00 | $0 | 21K |
| 2026-05-08 | Roberts Rebecca B | Director | Grant | 1K | $0.00 | $0 | 15K |
| 2026-05-08 | FREYMAN THOMAS C | Director | Grant | 1K | $0.00 | $0 | 128K |
| 2026-05-08 | WADDELL FREDERICK H | Director | Grant | 1K | $0.00 | $0 | 30K |
| 2026-05-08 | FALK THOMAS J | Director | Grant | 1K | $0.00 | $0 | 2K |
| 2026-05-08 | RAPP EDWARD J | Director | Grant | 1K | $0.00 | $0 | 46K |
| 2026-05-08 | AUSTIN ROXANNE S | Director | Grant | 1K | $0.00 | $0 | 40K |
| 2026-03-04 | Purdue David Ryan | SVP, Controller | Sell | 5K | $233.56 | $1.2M | 3K |
| 2026-03-02 | Siatis Perry C | EVP, GC AND SECRETARY | Sell | 3K | $235.26 | $612K | 5K |
| 2026-03-02 | Siatis Perry C | EVP, GC AND SECRETARY | Sell | 10K | $234.66 | $2.4M | 7K |
| 2026-03-02 | Siatis Perry C | EVP, GC AND SECRETARY | Sell | 6K | $233.51 | $1.3M | 18K |
| 2026-02-27 | Purdue David Ryan | SVP, Controller | Tax withholding | 2K | $232.08 | $489K | 8K |
| 2026-02-27 | Purdue David Ryan | SVP, Controller | Tax withholding | 3K | $232.08 | $625K | 8K |
| 2026-02-27 | Thakkar Roopal | EVP, R&D and CSO | Tax withholding | 8K | $232.08 | $1.9M | 52K |
| 2026-02-27 | Siatis Perry C | EVP, GC AND SECRETARY | Tax withholding | 15K | $232.08 | $3.4M | 23K |
| 2026-02-27 | Reents Scott T | EVP, CHIEF FINANCIAL OFFICER | Tax withholding | 22K | $232.08 | $5.0M | 39K |
| 2026-02-27 | Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | Tax withholding | 13K | $232.08 | $3.0M | 74K |
| 2026-02-27 | Stewart Jeffrey Ryan | EVP, CHIEF COMMERCIAL OFFICER | Tax withholding | 24K | $232.08 | $5.5M | 83K |
| 2026-02-27 | Michael Robert A. | CHAIRMAN OF THE BOARD AND CEO | Tax withholding | 37K | $232.08 | $8.5M | 179K |
| 2026-02-27 | SALEKI-GERHARDT AZITA | EVP, CHIEF OPERATIONS OFFICER | Tax withholding | 16K | $232.08 | $3.8M | 198K |
| 2026-02-27 | Crum Demetris D | EVP, CHIEF HR OFFICER | Tax withholding | 2K | $232.08 | $370K | 8K |
| 2026-02-25 | Siatis Perry C | EVP, GC AND SECRETARY | Sell | 22K | $230.00 | $5.1M | 38K |
| 2026-02-25 | Siatis Perry C | EVP, GC AND SECRETARY | Exercise or conversion | 7K | $192.86 | $1.4M | 61K |
| 2026-02-25 | Siatis Perry C | EVP, GC AND SECRETARY | Exercise or conversion | 8K | $175.28 | $1.4M | 53K |
| 2026-02-25 | Siatis Perry C | EVP, GC AND SECRETARY | Exercise or conversion | 7K | $149.62 | $1.1M | 45K |
| 2026-02-18 | Crum Demetris D | EVP, CHIEF HR OFFICER | Grant | 1K | $0.00 | $0 | 10K |
| 2026-02-18 | Crum Demetris D | EVP, CHIEF HR OFFICER | Grant | 1K | $0.00 | $0 | 8K |
| 2026-02-18 | Purdue David Ryan | SVP, Controller | Grant | 1K | $0.00 | $0 | 11K |
| 2026-02-18 | Purdue David Ryan | SVP, Controller | Grant | 1K | $0.00 | $0 | 9K |
| 2026-02-18 | Purdue David Ryan | SVP, Controller | Grant | 890 | $0.00 | $0 | 8K |
| 2026-02-18 | Purdue David Ryan | SVP, Controller | Grant | 3K | $0.00 | $0 | 7K |
| 2026-02-18 | Thakkar Roopal | EVP, R&D and CSO | Grant | 7K | $0.00 | $0 | 60K |
| 2026-02-18 | Thakkar Roopal | EVP, R&D and CSO | Grant | 3K | $0.00 | $0 | 54K |
| 2026-02-18 | Thakkar Roopal | EVP, R&D and CSO | Grant | 2K | $0.00 | $0 | 50K |
| 2026-02-18 | Thakkar Roopal | EVP, R&D and CSO | Grant | 6K | $0.00 | $0 | 48K |
| 2026-02-18 | Siatis Perry C | EVP, GC AND SECRETARY | Grant | 6K | $0.00 | $0 | 38K |
| 2026-02-18 | Siatis Perry C | EVP, GC AND SECRETARY | Grant | 6K | $0.00 | $0 | 32K |
| 2026-02-18 | Siatis Perry C | EVP, GC AND SECRETARY | Grant | 6K | $0.00 | $0 | 27K |
| 2026-02-18 | Siatis Perry C | EVP, GC AND SECRETARY | Grant | 16K | $0.00 | $0 | 21K |
| 2026-02-18 | Reents Scott T | EVP, CHIEF FINANCIAL OFFICER | Grant | 7K | $0.00 | $0 | 60K |
| 2026-02-18 | Reents Scott T | EVP, CHIEF FINANCIAL OFFICER | Grant | 8K | $0.00 | $0 | 53K |
| 2026-02-18 | Reents Scott T | EVP, CHIEF FINANCIAL OFFICER | Grant | 9K | $0.00 | $0 | 46K |
| 2026-02-18 | Reents Scott T | EVP, CHIEF FINANCIAL OFFICER | Grant | 25K | $0.00 | $0 | 37K |
| 2026-02-18 | Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | Grant | 6K | $0.00 | $0 | 87K |
| 2026-02-18 | Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | Grant | 5K | $0.00 | $0 | 81K |
| 2026-02-18 | Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | Grant | 5K | $0.00 | $0 | 76K |
| 2026-02-18 | Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | Grant | 13K | $0.00 | $0 | 71K |
| 2026-02-18 | Stewart Jeffrey Ryan | EVP, CHIEF COMMERCIAL OFFICER | Grant | 9K | $0.00 | $0 | 107K |
| 2026-02-18 | Stewart Jeffrey Ryan | EVP, CHIEF COMMERCIAL OFFICER | Grant | 9K | $0.00 | $0 | 98K |
| 2026-02-18 | Stewart Jeffrey Ryan | EVP, CHIEF COMMERCIAL OFFICER | Grant | 9K | $0.00 | $0 | 89K |
| 2026-02-18 | Stewart Jeffrey Ryan | EVP, CHIEF COMMERCIAL OFFICER | Grant | 26K | $0.00 | $0 | 79K |
| 2026-02-18 | Michael Robert A. | CHIEF EXECUTIVE OFFICER | Grant | 22K | $0.00 | $0 | 215K |
| 2026-02-18 | Michael Robert A. | CHIEF EXECUTIVE OFFICER | Grant | 14K | $0.00 | $0 | 193K |
| 2026-02-18 | Michael Robert A. | CHIEF EXECUTIVE OFFICER | Grant | 12K | $0.00 | $0 | 179K |
| 2026-02-18 | Michael Robert A. | CHIEF EXECUTIVE OFFICER | Grant | 34K | $0.00 | $0 | 167K |
| 2026-02-18 | SALEKI-GERHARDT AZITA | EVP, CHIEF OPERATIONS OFFICER | Grant | 7K | $0.00 | $0 | 214K |
| 2026-02-18 | SALEKI-GERHARDT AZITA | EVP, CHIEF OPERATIONS OFFICER | Grant | 7K | $0.00 | $0 | 207K |
| 2026-02-18 | SALEKI-GERHARDT AZITA | EVP, CHIEF OPERATIONS OFFICER | Grant | 6K | $0.00 | $0 | 200K |
| 2026-02-18 | SALEKI-GERHARDT AZITA | EVP, CHIEF OPERATIONS OFFICER | Grant | 17K | $0.00 | $0 | 194K |
| 2025-08-12 | SALEKI-GERHARDT AZITA | EVP, CHIEF OPERATIONS OFFICER | Sell | 42K | $198.42 | $8.4M | 177K |
| 2025-08-12 | SALEKI-GERHARDT AZITA | EVP, CHIEF OPERATIONS OFFICER | Exercise or conversion | 42K | $54.86 | $2.3M | 220K |
| 2025-08-05 | Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | Sell | 10K | $198.59 | $2.0M | 58K |
| 2025-08-05 | Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | Sell | 3K | $198.27 | $641K | 68K |
| 2025-05-09 | RAPP EDWARD J | Director | Grant | 1K | $0.00 | $0 | 34K |
| 2025-05-09 | Alpern Robert J | Director | Grant | 1K | $0.00 | $0 | 36K |
| 2025-05-09 | AUSTIN ROXANNE S | Director | Grant | 1K | $0.00 | $0 | 38K |
| 2025-05-09 | BURNSIDE WILLIAM H.L. | Director | Grant | 1K | $0.00 | $0 | 27K |
| 2025-05-09 | Davis Jennifer L. | Director | Grant | 1K | $0.00 | $0 | 3K |
| 2025-05-09 | Hart Brett J | Director | Grant | 1K | $0.00 | $0 | 19K |
| 2025-05-09 | MEYER MELODY B | Director | Grant | 1K | $0.00 | $0 | 16K |
| 2025-05-09 | Quaggin Susan E | Director | Grant | 1K | $0.00 | $0 | 3K |
| 2025-05-09 | Roberts Rebecca B | Director | Grant | 1K | $0.00 | $0 | 14K |
| 2025-05-09 | WADDELL FREDERICK H | Director | Grant | 1K | $0.00 | $0 | 29K |
| 2025-05-09 | FREYMAN THOMAS C | Director | Grant | 1K | $0.00 | $0 | 127K |
| 2025-05-09 | TILTON GLENN F | Director | Grant | 1K | $0.00 | $0 | 52K |
| 2025-05-09 | FALK THOMAS J | Director | Grant | 1K | $0.00 | $0 | 1K |
| 2025-03-31 | Stewart Jeffrey Ryan | EVP, CHIEF COMMERCIAL OFFICER | Sell | 26K | $209.49 | $5.4M | 86K |
| 2025-03-31 | Stewart Jeffrey Ryan | EVP, CHIEF COMMERCIAL OFFICER | Sell | 33K | $210.54 | $7.0M | 53K |
| 2025-03-31 | Stewart Jeffrey Ryan | EVP, CHIEF COMMERCIAL OFFICER | Exercise or conversion | 26K | $79.02 | $2.0M | 112K |
| 2025-03-31 | GONZALEZ RICHARD A | Director | Gift | 2K | $0.00 | $0 | 386K |
| 2025-03-14 | Reents Scott T | EVP, CHIEF FINANCIAL OFFICER | Sell | 18K | $212.34 | $3.7M | 12K |
| 2025-03-03 | Siatis Perry C | EVP, GC AND SECRETARY | Exercise or conversion | 7K | $149.62 | $1.1M | 15K |
| 2025-03-03 | Siatis Perry C | EVP, GC AND SECRETARY | Sell | 18K | $210.00 | $3.8M | 5K |
| 2025-03-03 | Siatis Perry C | EVP, GC AND SECRETARY | Exercise or conversion | 8K | $175.28 | $1.4M | 23K |
| 2025-03-03 | Siatis Perry C | EVP, GC AND SECRETARY | Exercise or conversion | 3K | $144.54 | $422K | 8K |
| 2025-03-03 | GONZALEZ RICHARD A | Director | Sell | 6K | $210.53 | $1.3M | 389K |
| 2025-03-03 | RICHMOND TIMOTHY J. | EVP, CHIEF HR OFFICER | Sell | 600 | $211.32 | $127K | 6K |
| 2025-03-03 | RICHMOND TIMOTHY J. | EVP, CHIEF HR OFFICER | Sell | 15K | $210.66 | $3.2M | 7K |
| 2025-03-03 | RICHMOND TIMOTHY J. | EVP, CHIEF HR OFFICER | Sell | 6K | $209.80 | $1.2M | 22K |
| 2025-02-28 | Siatis Perry C | EVP, GC AND SECRETARY | Sell | 3K | $205.38 | $558K | 12K |
| 2025-02-28 | Siatis Perry C | EVP, GC AND SECRETARY | Tax withholding | 8K | $205.02 | $1.6M | 15K |
| 2025-02-28 | Siatis Perry C | EVP, GC AND SECRETARY | Sell | 363 | $207.19 | $75K | 5K |
| 2025-02-28 | Siatis Perry C | EVP, GC AND SECRETARY | Sell | 7K | $206.62 | $1.4M | 5K |
| 2025-02-28 | GONZALEZ RICHARD A | Director | Tax withholding | 73K | $205.02 | $15.0M | 488K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON5 Form 144 notices on file for ABBV worth $21.7M at the prices reported; 1 in the last 90 days worth $8.2M. Latest: NICHOLAS DONOGHOE filed on 2026-08-14 to sell 32,710 shares ($8.2M) from 2026-08-14.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-08-14 | NICHOLAS DONOGHOEOfficer | 33K | $8.2M | 0.002% | 2026-08-14 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-26 | ROBERT J ALPERNDirector | 13K | $2.8M | 0.001% | 2026-05-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-06 | David R. PurdueOfficer | 5K | $1.2M | 0.000% | 2026-03-04 | Morgan Stanley Smith Barney LLC |
| 2026-03-02 | PERRY C SIATISOfficer | 19K | $4.4M | 0.001% | 2026-03-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-25 | PERRY C SIATISOfficer | 22K | $5.1M | 0.001% | 2026-02-25 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON1 holder reports 5% or more of ABBV in its latest filing, on Schedule 13G (passive). The holder is Vanguard Capital Management at 7.5% of the class (132,924,058 shares), filed 2026-04-29 for an event on 2026-03-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-04-29 | 13G | Vanguard Capital Managementinvestment adviser | 132.9M | 7.5% | 2026-03-31 |
| 2026-03-26 | 13G/Ano. 12 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
13F holders
Tracked managers holding ABBV at their latest 13F. JSON8 of the 30 tracked managers held ABBV at their latest 13F, $4.75B in total at quarter-end prices. Fisher Asset Management is the largest at $2.39B (0.7% of its portfolio) as of 2026-06-30. Over the prior quarter 7 added shares and 1 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Fisher Asset Management | 2026-06-30 | 9.5M | $2.39B | 0.71% | +406K |
| Citadel Advisors | 2026-06-30 | 3.2M | $797.6M | 0.09% | +2.7M |
| D. E. Shaw & Co. | 2026-06-30 | 2.1M | $529.0M | 0.25% | +1.4M |
| AQR Capital Management | 2026-06-30 | 2.0M | $507.1M | 0.18% | +1.1M |
| Millennium Management | 2026-06-30 | 1.5M | $381.6M | 0.14% | +841K |
| Point72 Asset Management | 2026-06-30 | 367K | $92.3M | 0.10% | new |
| Two Sigma Investments | 2026-06-30 | 198K | $49.9M | 0.04% | +20K |
| Bridgewater Associates | 2026-06-30 | 12K | $3.0M | 0.01% | -19K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) AbbVie reported revenue of $16.99B, up 10.2% from the same quarter a year earlier, and net income of $3.61B (2.03 diluted EPS). In FY 2025 it generated $19.03B of operating cash flow and spent $980.0M on buybacks and $11.66B on dividends.
- Cash
- $6.57B
- Equity
- -$5.93B
- Total assets
- $135.12B
- Shares outstanding
- 1,767,117,285
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $16.99B | $3.61B | 21.3% | 2.03 |
| Q1 FY 2026 | 2026-03-31 | $15.00B | $695.0M | 4.6% | 0.39 |
| Q4 FY 2025 | 2025-12-31 | $16.62B | $1.82B | 10.9% | 1.02 |
| Q3 FY 2025 | 2025-09-30 | $15.78B | $186.0M | 1.2% | 0.10 |
| Q2 FY 2025 | 2025-06-30 | $15.42B | $938.0M | 6.1% | 0.52 |
| Q1 FY 2025 | 2025-03-31 | $13.34B | $1.29B | 9.6% | 0.72 |
| Q4 FY 2024 | 2024-12-31 | $15.10B | -$22.0M | -0.1% | -0.02 |
| Q3 FY 2024 | 2024-09-30 | $14.46B | $1.56B | 10.8% | 0.88 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $61.16B | $4.23B | $19.03B | $1.21B | $980.0M | $11.66B |
| FY 2024 | 2024-12-31 | $56.33B | $4.28B | $18.81B | $974.0M | $1.71B | $11.03B |
| FY 2023 | 2023-12-31 | $54.32B | $4.86B | $22.84B | $777.0M | $1.97B | $10.54B |
| FY 2022 | 2022-12-31 | $58.05B | $11.84B | $24.94B | $695.0M | $1.49B | $10.04B |
| FY 2021 | 2021-12-31 | $56.20B | $11.54B | $22.78B | $787.0M | $934.0M | $9.26B |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-27 from the cover page.
What this page is
AbbVie in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows AbbVie (ABBV), SEC CIK 1551152, listed on NYSE, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-13.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-08-14.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-04-29.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-10-30.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-08-14.JSON and CSV
- Company record
- EDGAR filing index for CIK 1551152Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
- SYRESpyre Therapeutics
- SYYSysco
- TAT&T
- TAPMolson Coors
- TCOMTrip.com Group
Datasets
Frequently Asked Questions
How much of ABBV is sold short?
15,582,821 shares were held short at the 2026-10-15 settlement, 2.7 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is ABBV's daily short volume?
On 2026-11-02, 445,516 of the 3,135,464 ABBV shares reported to FINRA were sold short, 14.2% of the day's reported volume. Short volume is a flow for one day, not a position.
Does ABBV have fails to deliver?
The SEC's latest file shows 355 ABBV shares failed to deliver at settlement 2026-10-13. Fails are reported per settlement date and published twice a month with a lag.
Are ABBV insiders buying or selling?
Insiders at ABBV reported 1 open-market sell worth $8.2M in the last 90 days and no open-market buys. Latest filing: Donoghoe Nicholas (EVP, CHIEF BUS/STRAT OFFICER) on 2026-08-14.
Have ABBV insiders filed to sell?
5 Form 144 notices on file for ABBV worth $21.7M at the prices reported; 1 in the last 90 days worth $8.2M. Latest: NICHOLAS DONOGHOE filed on 2026-08-14 to sell 32,710 shares ($8.2M) from 2026-08-14.
Who owns 5% or more of ABBV?
1 holder reports 5% or more of ABBV in its latest filing, on Schedule 13G (passive). The holder is Vanguard Capital Management at 7.5% of the class (132,924,058 shares), filed 2026-04-29 for an event on 2026-03-31.
What did ABBV report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) AbbVie reported revenue of $16.99B, up 10.2% from the same quarter a year earlier, and net income of $3.61B (2.03 diluted EPS). In FY 2025 it generated $19.03B of operating cash flow and spent $980.0M on buybacks and $11.66B on dividends.
Which tracked 13F managers own ABBV?
8 of the 30 tracked 13F managers held ABBV shares at their latest filing, $4.75B in all. The largest: Ken Fisher's Fisher Asset Management (9.5M shares, $2.39B), Ken Griffin's Citadel Advisors (3.2M shares, $797.6M), D. E. Shaw & Co. (2.1M shares, $529.0M), Cliff Asness's AQR Capital Management (2.0M shares, $507.1M), Izzy Englander's Millennium Management (1.5M shares, $381.6M), Steve Cohen's Point72 Asset Management (367K shares, $92.3M). The table above lists all 8.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.